Cytori Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Thinly traded nano-cap biotech Cytori Therapeutics Inc, which has been trading in penny stock territory for about a year now, could see some activity in the wake of a company announcement Friday.

Cytori CFO Resigns, Biotech Restructures In Bid To Focus Resources On Lung Cancer Drug

Athersys

Understanding the basics of the stem cell sector.

The Stem Cell Triple Play: 3 Companies WIth Great Value Drivers

Cytori Therapeutics Inc.'s (CYTX) CEO Marc Hedrick on Q4 2018 Results - Earnings Call Transcript

News for Cytori Therapeutics Stock (CYTX)